Adalimumab is a fully humanized monoclonal IgG1 antibody and tumor necrosis factor α (TNFα) antagonist used in several indications, including moderate-to-severe plaque psoriasis and psoriatic arthritis. The gene discussed is TNF; the disease is psoriatic arthritis.